SUMMARY The efficacy and effect on cardiac function of verapamil 120 mg three times a day and atenolol 100mg once a day, singly and in combination, were evaluated in 15 patients with angina pectoris. While they were on the combination treatment four patients withdrew from the study. Episodes of angina pectoris and glyceryl trinitrate consumption were significantly reduced only on the combination. On the combination only four patients developed evidence of ischaemia during exercise compared with seven on verapamil and ten on atenolol. ST segment depression at peak exercise, assessed by 16 point precordial mapping, was reduced by all active treatments from 7 1 on placebo to 2-7, 0-9, and 0-6 mm on atenolol, verapamil, and the combination respectively. Mean left ventricular ejection fraction fell significantly from 60% on placebo to 53% on the combination but was unchanged on verapamil and atenolol.
53% on the combination but was unchanged on verapamil and atenolol.
Verapamil was an effective alternative to atenolol; the combination was the most effective treatment but was associated with a significant morbidity.
Although I adrenoceptor blockers remain the mainstay for the treatment of effort related angina pectoris, in a considerable number of patients they may cause troublesome side effects, are only partially effective, or are relatively contraindicated.
Recently calcium antagonists have been introduced into the management of the various forms of angina pectoris including that related to effort.' 3 The differing and possibly complementary actions of the P blockers and calcium antagonists raise the possibility that a combination of these two agents may have beneficial or detrimental interactions. 4 While it is generally accepted that the combination of the calcium antagonist nifedipine and a f blocker is safe in patients with normal ventricular function, 5 7 caution has been advised with the combination of verapamil and a ,B blocker because of the likely, and possibly detrimental, mutual potentiation of effects on cardiac conduction and contractility. ' 8 9 We have evaluated the effects of verapamil and atenolol, singly and in combination, on cardiac function in patients with stable angina.
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Accepted for publication 3 Novenber 1986 Patients and methods Fifteen patients (10 men) were recruited from the cardiology clinic of the Western Infirmary (table 1). All had chronic effort related angina pectoris with a stable pattern of symptoms for at least three months and none had pain at rest. All had an unequivocally positive exercise test for myocardial ischaemia ( > 0 1 mV ST segment depression occurring 80 ms after the J point) at the end of a two week single blind placebo run in period during which all other antianginal medication was withdrawn.
We excluded patients with appreciable chronic obstructive airways disease, severe hypertension (blood pressure > 170/1 10 mm Hg off all treatment), myocardial infarction within the previous three months, peripheral vascular disease, previous congestive cardiac failure, or evidence of pronounced conduction abnormalities on the electrocardiogram. Coronary arteriography was carried out in most patients after the study was completed.
TRIAL DESIGN There were four treatment periods each lasting three weeks. They were placebo, verapamil 120 mg three times a day, atenolol 100mg once a day, and the The work done to the onset of angina pectoris and ST depression was analysed by log rank analysis.15
Results
Four patients withdrew from the study and are not included in the results. The study was analysed for a possible order or crossover effect but this was not apparent.
SUBJECTIVE
Angina pectoris and glyceryl trinitrate consumption The mean frequency of angina pectoris was 30 0, 19-9, 16-8, and 7 6 episodes on placebo, atenolol, verapamil, and the combination respectively; only on the combination treatment was this reduction significant. Mean glyceryl trinitrate consumption was 37-1, 13-7, 9 0, and 5-9 tablets (all not significant). Patient number 10 experienced severe Findlay, MacLeod, Gillen, Elliott, Aitchison, Dargie angina pectoris on placebo with over one hundred attacks many of which required two glyceryl trinitrate tablets for the relief of pain. Removal of this outlier from the analysis considerably reduced the average placebo values and also the estimate of overall variability of glyceryl trinitrate consumption from + 8-9 to + 2-4 and frequency of angina pectoris from +43 to +2-9; this reduction in variability leads to improved treatment comparisons (table 2) . Overall the combination was the most effective treatment in reducing both the frequency of angina and glyceryl trinitrate consumption.
OBJECTIVE
Heart rate and blood pressure (tables 3 and 4) Verapamil and atenolol given alone significantly reduced erect and supine heart rate but had no effect on systolic or diastolic blood pressure. Resting heart rate was lowest on the combination but this was not significantly different from that on atenolol. The combination reduced both erect and supine, systolic and diastolic, blood pressure.
All active treatments significantly reduced the heart rate during exercise. This was most pro- There is a significant difference between variables that are not connected by a line. The rate pressure product was significantly reduced at rest and during exercise by all active treatments; the reduction was most marked on the combination. 16 point precordial electrocardiograpic mapping During exercise 11, 6, 3, and 2 patients developed ST segment depression and 10, 8, 5, and 3 developed angina on placebo, atenolol, verapamil, and the combination respectively. The work done to the onset of angina pectoris was significantly increased only on verapamil and the combination (p < 0 05 and p < 0-01); work done to the onset of ST segment depression was significantly improved on all active phases (p < 0-05, p < 0 005, and p < 0-001 for atenolol, verapamil, and the combination respectively). On the combination seven patients showed no evidence of exercise induced ischaemia (ST depression or angina) compared with four on verapamil and one on atenolol. Table 5 shows the area and sum of the ST segment depression immediately after exercise and during the 10 minute recovery period.
Twenty four hour ambulatory electrocardiographic monitoring The figure shows the mean hourly heart rate during Table 5 Mean area of ischaemia (positive points) and ST segment depression at peak exercise and over the 10 minute recovery period as assessed by 16 Combination of verapamil and ,B blockers in angina pectoris all objective and subjective indices of ischaemia than did atenolol but in general the combination was the most effective treatment. Although the reduction in the frequency of angina and in glyceryl trinitrate consumption was greatest during combination treatment, almost 50% of patients found that verapamil was the most acceptable treatment. On combination treatment there was a pronounced reduction in the rate pressure product during exercise, principally through a lowering of heart rate, which was significantly greater than that on atenolol alone. Though reduction in exercise tachycardia is an important factor in lowering myocardial oxygen consumption, the considerable fall in heart rate that occurred in some of our patients may not be entirely beneficial. It may lead to such a reduction in cardiac output that lethargy and fatigue will occur during even moderate exertion and it is possible that the subjective side effects observed resulted from this effect.
The negative inotropic and chronotropic effects of short term verapamil treatment are offset by the reflex increase in sympathetic activity consequent upon the fall in systemic vascular resistance.2" When verapamil is given for longer increased sympathetic activity is unlikely to persist. 22 In this study concentrations of plasma noradrenaline were similar (and normal) during all four treatment periods.
Resting left ventricular ejection fraction did not change on either of the active mono treatments, and though a significant fall has been reported on verapamil alone20 our findings resemble those of other investigators.3 9 17 18 On the combination treatment, however, mean left ventricular ejection fraction fell significantly and left ventricular failure developed in one patient. The increase in heart size and the development of dyspnoea and cardiac failure noted in other studies1 8 9 pamil concentrations in patients with coronary heart disease. We observed a modest rise in mean plasma concentrations of verapamil and nor-verapamil during combination treatment, which was not statistically significant. Plasma concentrations of verapamil and atenolol taken from patient 10 during his admission with cardiac failure (12 hours post-dose) were 448 and 276pmol/I respectively. Two days later (2 and 6 hours post-dosing), when the cardiac failure had resolved, the concentrations were 210 and 100pmol/I respectively, the lowest recorded in any patient. It may be that relief of hepatic congestion and increased renal perfusion improved metabolism and excretion and thus produced lower concentrations of these agents. In general, however, there was no obvious relation between plasma concentrations and observed and reported adverse reactions. It would be difficult to demonstrate such a relation, given the reported wide variability of plasma concentrations within individuals even over a 24 hour period.2930 Plasma concentrations in this study varied considerably during single and combination treatment. The absence of a consistent change during combination treatment does not suggest an important pharmacokinetic interaction; thus we conclude that the effects of this combination are principally the result of pharmacodynamic interaction.
Previously the safety and efficacy of combining verapamil with a f blocker have been studied mainly with propranolol' 8 8 and who had been studied in a previous trial' or under hospital supervision.8 9 23 31 Furthermore, in patients with poor effort capacity and depressed ventricular ejection fraction the frequency of adverse reactions rises significantly. 3' Reports of the combination of verapamil and atenolol in patients with angina pectoris are sparse. In one study adverse reactions were not reported35 and in another open study mild left ventricular failure occurred in five of 31 patients in whom verapamil was added to atenolol to control resistant angina.36 In contrast, we experienced quite frequent (and in one case severe) adverse reactions on the combination that were not readily predictable even with detailed knowledge of cardiac function. Despite a fall in mean left ventricular ejection fraction on the combination, these side effects occurred principally in those in whom important bradycardia occurred.
Thus in this study we have used these two drugs at doses that might be considered maximal. Both are effective antianginal agents and it is likely that they will be used in combination in patients with angina. If they are we advise that the dose of the drug currently being taken should be reduced when a low dose of the other drug is added, and that the doses should be titrated to achieve the maximum tolerated effective dose. The presence of a previous myocardial infarction should alert the clinician to the possibility that the patient may tolerate combination treatment poorly. Any documented bradycardia is an absolute contraindication to such treatment.
CONCLUSION
Verapamil was an effective and well tolerated alternative to atenolol in patients whose exercise capacity was severely limited by chest pain. Since most patients were incompletely controlled on / blockers before entry into the study, a selection bias against atenolol may have been a factor. The data do suggest, however, that it would be appropriate to change from a / blocker to verapamil if the patient's symptoms are not controlled, before adding another antianginal agent. The combination of these agents further improved overall effectiveness; it has a place in certain patients but caution is required in its use, which must be closely supervised. We thank Dr Rupinda Bhamra of the Poison's Unit at Guy's Hospital London for measuring plasma verapamil, nor-verapamil, and atenolol concentrations. Iain N Findlay was supported by a grant from the British Heart Foundation.
Appendix
(a) The presentation of results gives an F value and corresponding p value of the test of the hypothesis that all four treatments give the same average response for that variable. (b) The treatment comparisons P, placebo; V, verapamil; A, atenolol; and C, combination are given in a standard form to be interpreted as follows.
(i) P V A C means that there is no significant difference between the treatments C and A but both are different from V and also from P which itself is different from V.
(ii) P V A C means that the only significant differences were between C and each of the three treatments which themselves showed no significant differences between themselves.
(iii) P V A C means that C and A were not significantly different and that no separation between A, V, and P could be found-that is the only significant differences were between C and V and between C and P.
Virtually all F tests were referred to a F3 30 distribution. The pooled standard error (SE) of the mean for any variable is given after the mean values.
